COGT: Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for COGT
Across the 22 sessions after earlier COGT headlines, the stock closed higher 14 times and lower 8 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | COGT | SPY |
|---|---|---|---|
| May 12, 2026 | Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | +1.3% | -0.2% |
| May 5, 2026 | Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | +0.7% | +0.8% |
| Apr 21, 2026 | Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | -0.7% | -0.7% |
| Apr 17, 2026 | Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | +2.9% | +1.2% |
| Apr 1, 2026 | Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | -8.4% | +0.8% |
| Mar 16, 2026 | Jefferies resumed coverage on Cogent Biosciencesand 1 other headline that session | +4.9% | +1.0% |
Quantisnow market dataNASDAQ
COGT
Cogent Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for COGT
Full COGT profile on Quantisnow Follow COGT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time